共 413 条
[1]
Conlon KC(1996)Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors Ann Surg 223 273-279
[2]
Klimstra DS(2017)Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet. 389 1011-1024
[3]
Brennan MF(2016)Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 34 2541-2556
[4]
Neoptolemos JP(2017)Prognostic significance of new AJCC tumor stage in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy Am J Surg Pathol 41 1097-1104
[5]
Palmer DH(2017)Does size matter in pancreatic cancer? Reappraisal of tumour dimension as a predictor of outcome beyond the TNM Ann Surg 266 142-148
[6]
Ghaneh P(2019)Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05) J Clin Oncol 37 189-222
[7]
Psarelli EE(2018)Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial Ann Surg 268 215-4167
[8]
Valle JW(2016)Initial survival outcomes for the AGITG GAP study–a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC) J Clin Oncol 34 4105-44
[9]
Halloran CM(2017)Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review Cancer. 123 4158-210
[10]
Faluyi O(2018)The symptom experience of patients with advanced pancreatic cancer: an integrative review Cancer Nurs 41 33-332